Efficacy and Safety of Sintilimab Combined With Nab-paclitaxel and Tegio (aTS) as First-line Treatment of Unresectable Locally Advanced, Recurrent or Metastatic Adenocarcinoma of Gastric and Gastroesophageal Junction，a Phase II Clinical Study

NCT06241469 · clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
40
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Wu Jun